Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filipa Lynce

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|August 11, 2020
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathwayArielle L Heeke, Joanne Xiu, Andrew Elliott, et al.
Journal of Genetic Counseling|October 3, 2020
BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE studyFilipa Lynce, Ilana Schlam, Xue Geng, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2021
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancerFilipa Lynce, James T Williams, Meredith M Regan, et al.
Journal of Reconstructive Microsurgery|September 26, 2023
Preoperative Risk Factors for Lymphedema in Inflammatory Breast CancerLibby R Copeland-Halperin, Colby J Hyland, Goutam K Gadiraju, et al.
NPJ Breast Cancer|April 4, 2024
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancerPaolo Tarantino, Julieta Leone, Carlos T Vallejo, et al.
Frontiers in Oncology|September 28, 2020
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast CancerKatia Khoury, Antoinette R Tan, Andrew Elliott, et al.
Breast Cancer Research and Treatment|December 24, 2025
Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative databasePietro De Placido, Elizabeth Troll, Samuel M Niman, et al.
JAMA Network Open|April 9, 2026
Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast CancerJosé P Leone, Julieta Leone, Pietro De Placido, et al.
Breast Cancer Research and Treatment|October 24, 2022
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxanePaula R Pohlmann, Deena Graham, Tianmin Wu, et al.
Cancer|October 10, 2022
Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancerLaura E G Warren, Samuel M Niman, Marie C Remolano, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|August 11, 2020
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathwayArielle L Heeke, Joanne Xiu, Andrew Elliott, et al.
Journal of Genetic Counseling|October 3, 2020
BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE studyFilipa Lynce, Ilana Schlam, Xue Geng, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2021
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancerFilipa Lynce, James T Williams, Meredith M Regan, et al.
Journal of Reconstructive Microsurgery|September 26, 2023
Preoperative Risk Factors for Lymphedema in Inflammatory Breast CancerLibby R Copeland-Halperin, Colby J Hyland, Goutam K Gadiraju, et al.
NPJ Breast Cancer|April 4, 2024
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancerPaolo Tarantino, Julieta Leone, Carlos T Vallejo, et al.
Frontiers in Oncology|September 28, 2020
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast CancerKatia Khoury, Antoinette R Tan, Andrew Elliott, et al.
Breast Cancer Research and Treatment|December 24, 2025
Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative databasePietro De Placido, Elizabeth Troll, Samuel M Niman, et al.
JAMA Network Open|April 9, 2026
Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast CancerJosé P Leone, Julieta Leone, Pietro De Placido, et al.
Breast Cancer Research and Treatment|October 24, 2022
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxanePaula R Pohlmann, Deena Graham, Tianmin Wu, et al.
Cancer|October 10, 2022
Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancerLaura E G Warren, Samuel M Niman, Marie C Remolano, et al.
Pageof 10